Proto-Oncogene Proteins c-bcl-2
"Proto-Oncogene Proteins c-bcl-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
| Descriptor ID |
D019253
|
| MeSH Number(s) |
D12.644.360.075.718 D12.776.476.075.718 D12.776.624.664.700.169
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-2- Proto-Oncogene Proteins c-bcl-2
- Proto Oncogene Proteins c bcl 2
- c-bcl-2, Proto-Oncogene Proteins
- bcl-2 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-2
- bcl 2 Proto Oncogene Proteins
- c-bcl-2 Proteins
- c bcl 2 Proteins
B-Cell Leukemia 2 Family Proteins- B-Cell Leukemia 2 Family Proteins
- B Cell Leukemia 2 Family Proteins
- BCL2 Family Proteins
- Family Proteins, BCL2
- Proteins, BCL2 Family
- BCL2 Proteins
- Proteins, BCL2
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-2" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 3 | 2 | 5 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 4 | 7 |
| 2000 | 3 | 1 | 4 |
| 2001 | 2 | 3 | 5 |
| 2002 | 1 | 3 | 4 |
| 2003 | 3 | 6 | 9 |
| 2004 | 4 | 5 | 9 |
| 2005 | 1 | 11 | 12 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 5 | 6 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 2 | 3 |
| 2012 | 3 | 0 | 3 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 3 | 3 |
| 2015 | 3 | 6 | 9 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 1 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 4 | 6 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-2" by people in Profiles.
-
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025 Feb 11; 9(3):473-487.
-
Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases. Mod Pathol. 2025 May; 38(5):100710.
-
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025 Jan 01; 110(1):78-91.
-
High-grade B-cell lymphomas: Double hit and non-double hit. Hum Pathol. 2025 Feb; 156:105700.
-
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia. Cells. 2024 11 20; 13(22).
-
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations. Expert Rev Hematol. 2024 Dec; 17(12):935-946.
-
Impact of Myc-Altered Pathology on Radiation Therapy Efficacy Among Patients With Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Study by ILROG. Int J Radiat Oncol Biol Phys. 2025 Apr 01; 121(5):1237-1247.
-
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024 Dec; 636(8041):241-250.
-
Precision medicine in AML: overcoming resistance. Int J Hematol. 2024 Oct; 120(4):439-454.
-
Apoptosis Pathway-Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma. Am J Dermatopathol. 2024 Jul 01; 46(7):410-415.